The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors

Methods

Volumn 52, Issue 4, 2010, Pages 301-306

  Kapadia, Roxna ^a   Coffey, Matt C ^a  

^a ONCOLYTICS BIOTECH INC   (Canada)

Author keywords

Anti reovirus antibodies; Cancer; Clinical trials; Immunohistochemistry; In situ hybridization; Oncolytic; REOLYSIN; Reovirus

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ONCOLYTIC VIRUS; PACLITAXEL; RAS PROTEIN; REOLYSIN; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG SPECIFICITY; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REOVIRUS; REVIEW; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAMMALIAN ORTHOREOVIRUS 3; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; VIRUS REPLICATION;

ADENOVIRIDAE; DNA VIRUSES; MAMMALIAN ORTHOREOVIRUS 3; ORTHOREOVIRUS; RNA VIRUSES;

EID: 78349304612     PISSN: 10462023     EISSN: 10959130     Source Type: Journal    
DOI: 10.1016/j.ymeth.2010.08.011     Document Type: Review

References (35)

1. Nirbert M.L., Schiff L.A., Fields B.N. Reoviruses and their replication. Fundamental Virology 1996, Lippincott-Raven Publishers, Philadelphia. third ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
2. Paul R.W., Choi A.H., Lee P.W. Virology 1989, 172:382-385.
3. Barton E.S., Forrest J.C., Connolly J.L., et al. Cell 2001, 104:441-451.
4. Hashiro G., Loh P.C., Yau J.T. Arch. Virol. 1977, 54:307-315.
5. Duncan M.R., Stanish S.M., Cox D.C. J. Virol. 1978, 28:444-449.
6. Strong J.E., Coffey M.C., Tang D., Sabinin P., Lee P.W. EBMO J. 1998, 17:3351-3362.
7. Duursma A.M., Agami R. Semin. Cancer Biol. 2003, 13:267-273.
8. Bos J.L. Cancer Res. 1989, 49:4682-4689.
9. Norman K.L., Lee P.W. Drug Discov. Today 2005, 10:847-855.
10. Sei S., Mussio J.K., Yang Q., et al. Mol. Cancer 2009, 8:47.
11. Twigger K., Vidal L., White C.L., et al. Clin. Cancer Res. 2008, 14:912-923.
12. Hirasawa K., Nishikawa S.G., Norman K.L., Coffey M.C., et al. Cancer Res. 2003, 63:348-353.
13. Qiao J., Wang H., Kottke T., White C.L., et al. Clin. Cancer Res. 2008, 14:259-269.
14. M. Lolkema, K. Harrington, J. Evans et al., A phase-I study of the combination of intravenous reovirus (REOLYSIN®) and gemcitabine in patients with advanced cancer, ECCO ESMO Poster No. 1235, 2009.
15. S.M. Rudman, C. Comins, D. Mukherji et al., Results of a phase I study to evaluate the feasibility, safety, and biological effects of intravenous administration of wild-type reovirus with docetaxel to patients with advanced malignancies, J. Clin. Oncol. Abst. e13524, 2009.
16. E. Karapanagiotou, H.S. Pandha, G. Hall, J. Chester et al., Phase I/II trial of oncolytic reovirus (REOLYSIN®) in combination with carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN), AACR EORTC Poster, Boston, 2009.
17. Strong J.E., Tang D., Lee P.W.K. Virology 1993, 197:405-411.
18. Coffey M.C., Strong J.E., Forsyth P., et al. Science 1998, 282:1332-1334.
19. White C.L., Twigger K.R., Vidal L., et al. Gene Therapy 2008, 15:911-920.
20. Smakman N., Van Der Bilt J.D., Van Den Wollenberg D.J., et al. Cancer Gene Ther. 2006, 13:815-818.
21. Kottke T., Thompson J., Diaz R.M., Pulido J., et al. Clin. Cancer Res. 2009, 15:561-569.
22. C. Coomins, J. Spicer, A. Protheroe, et al., A Phase 1 study to evaluate systemic wild-type reovirus (REOLYSIN(R)) in combination with docetaxel in patients with advanced malignancies, in: International Society for Biological Therapy of Cancer 23rd Annual Meeting Poster 951 (2008).
23. Errington F., Steele L., Prestwich R., Harrington K.J. J. Immunol. 2008, 180:6018-6026.
24. D.G Morris, P.A Forsyth, A.H Paterson et al., A Phase I clinical trial evaluation intralesional Reolysin (reovirus) in histological confirmed malignancies, Proc. Am. Soc. Clin. Oncol. Poster 24a, Abstr. 92, 2002.
25. Thirukkumaran C.M., Nodwell M.J., Hirasawa K., et al. Cancer Res. 2010, 70:2435-2444.
26. Vidal L., Pandha H.S., Yap T.A., White C.L., et al. Clin Cancer Res. 2008, 14:7127-7137.
27. Gollamudi R., Ghalib M.H., Desai K.K., et al. Invest. New Drugs 2010, 28:641-649.
28. Parker J.S.L., Broering T.J., Kim J., et al. Journal of Virology 2002, 76:4483-4496.
29. M.A. Phelps, O.M. Cohn, D.M. O'Malley et al., Reovirus replication in ovarian and peritoneal tumors after intravenous administration, AACR Poster Abs 2594 (2010).
30. D.E. Cohn, G. Nuovo, M.C. Coffey et al., Phase I/II trial of reovirus serotype 3–Dearing strain in patients with recurrent ovarian cancer, ASCO Poster Abs 48844 (2010).
31. Pandha H.S., Heinemann L., Simpson G.R., Melcher A., et al. Clin. Cancer Res. 2009, 15:6158-6166.
32. Harrington K.J., Karapanagiotou E.M., Roulstone V., et al. Clin. Cancer Res. 2010, 16:3067-3077.
33. Nagano S., Perentes J.Y., Jain R.K., Boucher Y. Cancer Res. 2008, 68:3795-3802.
34. Bronstad A., Berg A., Reed R.K. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H963-H968.
35. Griffon-Etienne G., Boucher Y., Brekken C., et al. Cancer Res. 1999, 59:3776-3782.